ASSOCIATION OF FIB4 SCORE WITH DISEASE PROGRESSION IN REAL-WORLD POPULATIONS DIAGNOSED WITH NAFLD/NASH OR AT RISK OF NASH IN US CLINICAL PRACTICE

被引：0
|
作者：
Lai, Michelle
Broestl, Jeremy
Frick, Andrew
Haubrich, Richard
Koch, Bruce
Milligan, Scott
Natha, Macky
Younossi, Zobair M.
Afdhal, Nezam H.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1474
引用
收藏
页码：S1416 / S1416
页数：1
相关论文
共 50 条
  • [21] Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in US Adults
    Wang, Tiansheng
    Yang, Jeff Y.
    Buse, John B.
    Pate, Virginia
    Tang, Huilin
    Barnes, Edward L.
    Sandler, Robert S.
    Sturmer, Til
    DIABETES CARE, 2019, 42 (11) : 2065 - 2074
  • [22] Increasing Healthcare Resource Utilization (HCRU) and Costs Associated with Advanced Liver Disease - a Multivariate Analyses of Real-World Medicare Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients
    Gordon, Stuart C.
    Fraysse, Jeremy
    Li, Suying
    Wong, Robert J.
    HEPATOLOGY, 2018, 68 : 573A - 573A
  • [23] Dosage Pattern of Adalimumab in Real-World Clinical Practice and Predictors of Dosage Increase in Patients with Crohn's Disease in the US
    Loftus, Edward V.
    Pan, Xiaoyun
    Zurawski, Pete
    Chao, Jingdong
    Mulani, Pervez
    GASTROENTEROLOGY, 2009, 136 (05) : A175 - A176
  • [24] Fibrosis-4 Score (FIB-4) Provides Consistent Assessment of Healthcare Costs and Healthcare Resource Utilization (HCRU) Among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Fibrosis
    Gordon, Stuart C.
    Ozbay, Burak
    Parker, Emily
    Korrer, Stephanie
    Wong, Robert J.
    HEPATOLOGY, 2018, 68 : 617A - 618A
  • [25] Applying Clinical Risk Scores in Real-World Practice The CHA2DS2-VASc Score in Atrial Fibrillation
    Barnes, Geoffrey D.
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (21) : 2154 - 2156
  • [26] RENAL DISEASE PREVALENCE AND ASSOCIATION WITH HEPATIC FIBROSIS MEASURED BY FIB4 SCORE AMONG US PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS)
    Holmberg, S. D.
    Moorman, A. C.
    Tong, X.
    Spradling, P. R.
    Teshale, E. H.
    Gordon, S. C.
    Boscarino, J. A.
    Vijayadeva, V.
    Schmidt, M. A.
    Rupp, L. B.
    Lu, M.
    Xu, F.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S597 - S598
  • [27] Real-World Health-Care Costs Impacted by Diabetes Mellitus (DM) among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Liver Diseases (AdvLD)
    Wong, Robert
    Kachru, Nandita
    Martinez, Diane
    Moynihan, Meghan
    Ozbay, A. Burak
    Gordon, Stuart
    DIABETES, 2019, 68
  • [28] Additional ASCVD Risk Factors for Patients With Diabetes: FIB-4 Score and NLR Are Higher in Adults With Diabetes and Current Risk Enhancers vs No Risk Enhancers in Real-World Evidence
    Chapagain, Himal
    Alish, Yousef
    Becich, Michael
    Bradley, Alison
    Fernandez, Soledad
    Ford, Dan
    Hwang, Wenke
    Jeong, Jong
    Jurczak, Martha
    Kirchner, H. Lester
    McTigue, Kathleen M.
    Morgan, Richard
    Paranjape, Anuradha
    Thomas, Neena
    Williams, David
    Arnold, Jonathan
    CIRCULATION, 2022, 146
  • [29] CLINICAL CHARACTERISTICS AND FIB-4 RISK STRATIFICATION OF PRIMARY CARE PATIENTS WITH OBESITY, DIABETES, OR BOTH: REAL-WORLD IMPLICATIONS FOR ADOPTING A FIB-4 REFERRAL ALGORITHM TO DETECT METABOLIC DYSFUNCTION-ASSOCIATION STEATOTIC LIVER DISEASE (MASLD) WITH ADVANCED FIBROSIS
    Chu, Janet
    Khalili, Mandana
    Goldman, Max
    Hameed, Bilal
    Ha, Nghiem
    Fox, Rena
    HEPATOLOGY, 2024, 80 : S868 - S869
  • [30] Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice
    Aviles Bueno, Beatriz
    Soler, Maria Jose
    Perez-Belmonte, Luis
    Jimenez Millan, Anabel
    Rivas Ruiz, Francisco
    Garcia de Lucas, Maria Dolores
    CLINICAL KIDNEY JOURNAL, 2022, 15 (08) : 1593 - 1600
12345